FDA Approves At-Home Starting Dose for Lecanemab, Marking First Subcutaneous Initiation ...

FDA approves at-home subcutaneous self-injection initiation for lecanemab (Alzheimer's monoclonal antibody), replacing intravenous infusion clinic visits with 500 mg weekly doses via two 250 mg injections for early disease. This is the first subcutaneous starting option for anti-amyloid AD treatment, removing a major treatment access barrier.

This Wire brief sits within Fusion42's coverage of Digital Health.